Merck Past Earnings Performance

Past criteria checks 3/6

Merck has been growing earnings at an average annual rate of 26.1%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 11.4% per year. Merck's return on equity is 19%, and it has net margins of 16.4%.

Key information

26.1%

Earnings growth rate

26.1%

EPS growth rate

Pharmaceuticals Industry Growth20.4%
Revenue growth rate11.4%
Return on equity19.0%
Net Margin16.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Merck makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

IDX:MERK Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24949,799155,585203,4020
31 Dec 23961,434178,240200,9880
30 Sep 231,035,913160,481193,7300
30 Jun 231,023,241147,802194,8460
31 Mar 231,084,164163,535186,5620
31 Dec 221,124,600179,838190,2880
30 Sep 221,147,548163,618202,4450
30 Jun 221,157,128173,520201,5620
31 Mar 221,112,601140,958212,1230
31 Dec 211,064,395131,661208,2650
30 Sep 211,002,110134,624202,9420
30 Jun 21879,843121,326200,2670
31 Mar 21746,96090,227187,0390
31 Dec 20655,84771,902185,4890
30 Sep 20686,477116,256180,3090
30 Jun 20710,680104,255186,5550
31 Mar 20743,720101,692197,1130
31 Dec 19744,63578,257198,8140
30 Sep 19649,092-1,407205,1600
30 Jun 19633,30213,257196,3270
31 Mar 19633,74728,904181,2360
31 Dec 18611,95837,378168,1440
30 Sep 18144,570-65,6563,3430
30 Jun 18270,973-40,95051,2640
31 Mar 18407,044-16,297100,8910
31 Dec 17582,00229,455159,2090
30 Sep 171,125,749179,358340,1800
30 Jun 171,063,319157,481326,6350
31 Mar 171,045,176159,314338,0900
31 Dec 161,034,807153,843327,6040
30 Sep 161,036,484146,492336,7650
30 Jun 161,031,758149,614327,1990
31 Mar 161,018,683152,613311,6700
31 Dec 15983,446142,545311,5140
30 Sep 15976,678155,763302,1010
30 Jun 15963,813165,213292,7550
31 Mar 15925,146153,964282,3120
31 Dec 14863,208151,050264,3550
30 Sep 14524,829109,157219,0760
30 Jun 14582,779103,945238,2530
31 Mar 14657,357112,622248,7700
31 Dec 13805,746147,136255,2910
30 Sep 131,118,662156,150303,6240

Quality Earnings: MERK has high quality earnings.

Growing Profit Margin: MERK's current net profit margins (16.4%) are higher than last year (15.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MERK's earnings have grown significantly by 26.1% per year over the past 5 years.

Accelerating Growth: MERK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MERK had negative earnings growth (-4.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-4.9%).


Return on Equity

High ROE: MERK's Return on Equity (19%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.